Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2021-09-06 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
重大资产购买暨关联交易报告书（草案）（三次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产购买暨关联交易报告书（草案）" which translates to "Major Asset Purchase and Related Party Transaction Report (Draft)". It includes detailed sections such as transaction overview, asset evaluation, legal opinions, financial data, risk factors, and management discussion and analysis. The document is lengthy (15,000 characters) and contains substantive financial and operational information related to a significant asset acquisition and related party transaction. It is not a simple announcement or a brief summary but a comprehensive report detailing the transaction, its impact, and associated risks. This type of document aligns with filings related to capital or financing activities, specifically major asset purchases and related party transactions. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-09-06 Chinese
独立董事关于第五届董事会第十三次（临时）会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's 13th interim board meeting of the 5th board. It discusses a major asset acquisition and related audit reports, referencing regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes independent directors' approval of audit reports and a draft report on a major asset purchase and related party transaction. The content focuses on governance and compliance related to a significant transaction rather than presenting full financial statements or detailed financial results. The document length is short (1194 characters), and it is a formal opinion related to a board meeting and transaction approval, not a full audit report or annual report. This fits best under Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on a major transaction and related audit reports, rather than the audit report itself or a full financial report.
2021-09-06 Chinese
第五届监事会第十三次（临时）会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 盈康生命科技股份有限公司 regarding the approval of audit reports and a major asset purchase report related to a significant asset restructuring transaction. It includes details about the meeting, voting results, and references to related reports disclosed elsewhere. The document does not contain the full audit reports or financial statements themselves but rather the Supervisory Board's decisions and approvals. It is an official announcement of meeting resolutions and approvals related to major asset restructuring and audit reports, not the reports themselves. Therefore, it fits best under Regulatory Filings (RNS) as it is a formal disclosure of meeting resolutions and approvals without the full report content.
2021-09-06 Chinese
北京市金杜律师事务所关于公司重大资产购买暨关联交易之补充法律意见书（二）
Legal Proceedings Report Classification · 95% confidence The document is a detailed legal opinion letter from a law firm (北京市金杜律师事务所) regarding a major asset purchase and related party transaction by 盈康生命科技股份有限公司. It references prior legal opinion letters, updates on transaction terms, approvals, qualifications of parties, asset details, litigation, and regulatory compliance. The document is a supplementary legal opinion letter (补充法律意见书（二）) related to a major asset acquisition and restructuring transaction. It is not a financial report, earnings release, or investor presentation. It is a legal proceeding related document providing legal opinions on a corporate transaction. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length (over 14,000 characters) and detailed legal content confirm it is not a mere announcement or certification but a substantive legal report.
2021-09-06 Chinese
苏州广慈肿瘤医院有限公司2021年1-6月、2020年度、2019年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 苏州广慈肿瘤医院有限公司 covering the periods 2021 1-6 months, 2020 full year, and 2019 full year. It includes detailed financial statements such as balance sheets, income statements, cash flow statements, and equity changes, along with extensive notes and auditor's opinions. The presence of the auditor's opinion, audit basis, key audit matters, and detailed financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). H1 2021
2021-09-06 Chinese
第五届董事会第十三次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's fifth board of directors' thirteenth (extraordinary) meeting. It details the meeting's convening, attendance, and voting results on matters related to a major asset restructuring and related audit reports. The document includes references to audit reports and transaction proposals but does not contain the full audit reports or financial statements themselves. It also mentions that the matters will be submitted to the shareholders' meeting for approval. The document is a board meeting resolution announcement, focusing on board decisions and management information rather than the full audit report or annual report. Therefore, it fits best under Board/Management Information (MANG). The document length is under 5,000 characters and is a detailed announcement of board decisions, not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2021-09-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.